The NF-kB Pathway as Therapeutic Target
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (1 November 2021) | Viewed by 8289
Special Issue Editor
2. Department of Surgery, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
Interests: cell signalling in inflammation; autoimmunity and cancer
Special Issue Information
Dear Colleagues,
In 2021, the field will mark 35 years of investigating how NF-kB is regulated and regulates a wide array of physiological functions. An expansive body of research has made fundamental insights into mechanisms of cell signalling, cell death, and innate and adaptive immunity. Along the way, the role of NF-kB in normal physiology and the dysregulation of this pathway in human diseases has been well established. At the same time, there has been massive growth in efforts to target specific signalling pathways in order to manipulate the immune response and treat auto-immune, inflammatory, and oncological diseases. However, and despite the clear contribution of NF-kB to the aetiology and pathophysiology of various diseases, the impact of therapies targeting NF-kB has been far more limited than was once predicted. This Special Issue of Cells welcomes original research and review papers that review the role of NF-kB in human health; explore past and ongoing efforts to target NF-kB in disease; and provide perspectives on future directions in NF-kB research and NF-kB drug development.
Dr. Matthew S. Hayden
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NF-kB
- inflammation
- immuno-therapy
- IKK
- immunomodulatory compounds
- immuno-oncology
- anti-inflammatory
- cytokines
- toll-like receptors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
